Humana pulling out of ACA markets after antitrust lawsuit

Hours after the federal government filed an antitrust lawsuit against Humana’s proposed sale to Aetna, Humana announced it wouldn’t offer plans on Affordable Care Act exchanges in several states 2017.

“The company has also notified relevant DOIs of its intent to discontinue certain on-exchange Individual products across a number of geographies for 2017 and exit substantially all Affordable Care Act (ACA) compliant off-exchange Individual markets,” Humana said in its new earnings guidance report. “As a result, the company’s 2017 geographic presence for its Individual offerings is expected to cover no more than 156 counties across 11 states, down from 1,351 counties across 19 states in 2016.”

Humana had first said in May it would leave exchanges after reporting a 21 percent decline in enrollment in marketplace plans. In contrast, its proposed buyer, Aetna, has indicated it may expand its exchange offerings in 2017.

Opponents of the Affordable Care Act have pointed to departures of major insurers like Humana to back up arguments the law isn’t working. Sen. Ben Sasse, R-Neb., told POLITICO after the announcement: “This doesn’t look like a market—it looks like a death spiral.”

Other health experts have disagreed. UCLA Center for Health Policy Research Director Gerald Kominski, PhD, told HealthExec in June argued insurer departures aren’t signs of a death spiral, but “lobbying for continuation of reinsurance payments,” a program which is set to expire after 2016. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup